By Christy A. Eatmon, Global SME, Sterile Drug Product, Thermo Fisher Scientific; Frank V. Ritacco, Director, Scientific and Technical Affairs, Thermo Fisher Scientific; and Elena Gontarz, Manager, Scientific and Technical Affairs, Thermo Fisher Scientific
Late-stage drug development efforts have many moving parts as projects push toward commercialization. During this critical time, companies often take a good long look at their vendors and evaluate their options for scale up to commercial launch. Is your CDMO an asset or a hindrance in this process? How can you recognize whether your partners really contribute everything they can to your end goal of commercialization?
This article focuses on 10 red flags that could signal it is time to start looking elsewhere for a CDMO that can efficiently bring your project to commercialization while steering clear of potential roadblocks along the way.